Premium
P3‐298: The safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BMS‐708163 in young and elderly subjects
Author(s) -
Tong Gary,
Wang Jun-Sheng,
Sverdlov Alex,
Huang Shu-Pang,
Slemmon Randy,
Croop Robert,
Castaneda Lorna,
Gu Huidong,
Wong Oi,
Li Hewei,
Berman Robert M.,
Smith Christina,
Albright Charles F.,
Dockens Randy,
Arroyo Santiago
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1798
Subject(s) - medicine , tolerability , pharmacodynamics , adverse effect , pharmacokinetics , placebo , rash , pharmacology , gastroenterology , anesthesia , pathology , alternative medicine
improved cognitive function in a mouse model of AD (APP/PS1). Methods: To track BMDCs, bone marrow harvested from the mice carrying green fluorescent protein (GFP) was transplanted to the APP/PS1 mice. Thereafter, SCF+G-CSF were subcutaneous administered for 12 days, beginning at the age of 8 months when Ab plaques had appeared in the brain. To evaluate special learning and memory, water maze test was performed before and 9 months after treatment. Results: We observed that SCF+G-CSF-treated mice showed significantly shorter escape latency and that the number of senile plaques was significantly reduced by SCF+G-CSF treatment. In addition, a significant high number of GFP+/Iba1+ cells surrounding Ab plaques was seen in SCF+G-CSF-treated mice. Conclusions: These data suggest that SCF+G-CSF treatment may delay AD progress by enhancing clearance of Ab deposits via BM-derived microglial cells. These data would help in developing an effective treatment to improve health of AD.